Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study
Vascular Pharmacology · 2024
DOI: 10.1016/j.vph.2024.107382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular Pharmacology, 2024. Verfasst von Caner Vizdiklar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey. Hauptthemen laut MEDLINE: COVID-19, Hypolipidemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: COVID-19 restrictions prompted changes in chronic disease management and lifestyle modifications, potentially altering cardiometabolic indicators and lipid-lowering pharmacotherapy patterns. We aimed to assess lipid-lowering drug (LLD) utilization trends during COVID-19 restrictions. METHODS: We obtained nationwide outpatient drug sales and prescribing data for 01.03.2018-31.12.2022 from IQVIA™ Turkey. We evaluated average monthly LLD consumption, their costs, and quarterly prescribing levels in three periods: "before restrictions" (BfR, 01.03.2018-31.03.2020), "during restrictions" (DuR, 01.04.2020-31.03.2022), and "after restrictions" (AfR, 01.04.2022-31.12.2022). Drug utilization was measured via "defined daily dose/1000 inhabitants/day" (DID) metric. RESULTS: LLD utilization increased from 25.4 ± 3.1 DID in BfR to 36.2 ± 6.8 DID in DuR (p < 0.001), and to 42.6 ± 5.3 DID in AfR (p < 0.001 vs. BfR). Statin consumption significantly rose from 22.0 ± 3.0 DID in BfR to 31.6 ± 6.3 DID in DuR (p < 0.001), and further to 37.6 ± 4.7 DID in AfR (p < 0.01 vs. DuR). High-intensity statin consumption elevated by 115.9% in AfR compared to baseline (p < 0.001). Prescribing of LLDs decreased from 12.5 ± 0.6 DID in BfR to 7.2 ± 1.2 DID in DuR (p < 0.001), later reached 13.6 ± 3.8 DID in AfR (p < 0.001 vs. DuR), with prescribing for ongoing users following similar trend. Expenditure on LLDs increased from €8.4 m ± 0.9 m in BfR to €11.4 m ± 2.0 m in DuR (p < 0.001) and to €12.8 m ± 1.9 m in AfR (p < 0.001 vs. BfR). CONCLUSIONS: This study revealed a surge in consumption of LLDs in Turkey following the onset of the COVID-19 pandemic. This rise might be related to practices facilitating drug access, in addition to potentially greater adherence, or the necessity for more intense pharmacotherapy due to elevated cardiovascular risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey.
- Department of Medical Pharmacology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey; Hypertension and Atherosclerosis Research Centre, Marmara University, Istanbul, Turkey.
- Division of General Internal Medicine, Department of Internal Medicine, School of Medicine, Marmara University, Istanbul, Turkey.
- Department of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey; Hypertension and Atherosclerosis Research Centre, Marmara University, Istanbul, Turkey. Electronic address: aakici@marmara.ed…
Zitieren
APA
Vizdiklar, C., Aydin, V., Tazegul, G., Kaskal, M., & Akici, A. (2024). Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2024.107382
Vancouver
Vizdiklar C, Aydin V, Tazegul G, Kaskal M, Akici A. Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study. Vascular Pharmacology. 2024. doi:10.1016/j.vph.2024.107382
BibTeX
@article{Vizdiklar2024,
author = {Vizdiklar, Caner and Aydin, Volkan and Tazegul, Gokhan and Kaskal, Mert and Akici, Ahmet},
title = {Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study},
journal = {Vascular Pharmacology},
year = {2024},
doi = {10.1016/j.vph.2024.107382}
}
EUVIMED